Patents by Inventor Paul Ashton

Paul Ashton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240058264
    Abstract: Formulations and intravitreal implants containing nintedanib can be used in methods for the treatment of back-of-the-eye diseases.
    Type: Application
    Filed: August 16, 2023
    Publication date: February 22, 2024
    Inventors: Paul ASHTON, Jianbing CHEN, Florian Andreas COLBATZKY, Hong GUO, Laibin LUO, Kerstin Julia SCHAEFER
  • Publication number: 20220226544
    Abstract: Provided herein are devices and methods for treating inflammation and pain of articular joints (e.g., the knee). An implantable device includes an elongate body extending from a proximal end to a distal end, a flange disposed at the proximal end, a bore extending from an opening at the proximal end into the elongate body, one or more fixation members disposed on an outer surface of the elongate body, and a payload (e.g., a drug-polymer core) having a therapeutic agent disposed within the bore. The payload has a substantially constant surface area on an exposed portion throughout elution of the therapeutic agent after the implantable device is implanted in a body. The therapeutic agent is configured to elute using zero-order kinetics, constantly and continuously at an amount that is above a predetermined lower threshold and does not exceed a predetermined upper threshold unlike a pulse-dose injection.
    Type: Application
    Filed: January 14, 2022
    Publication date: July 21, 2022
    Inventors: Robert N. Hotchkiss, Paul Ashton, Martin Nazzaro
  • Patent number: 11026885
    Abstract: This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: June 8, 2021
    Assignee: EYEPOINT PHARMACEUTICAS, INC.
    Inventors: Paul Ashton, Leigh T. Canham, Christian Barnett
  • Patent number: 10404817
    Abstract: Systems, methods, and non-transitory computer readable media can obtain a first event stream including one or more events of a first type, where each event of the first type is associated with a timestamp. A second event stream including one or more events of a second type can be obtained, where each event of the second type is associated with a timestamp. The first event stream and the second event stream can be merged to generate information associated with a metric relating to a system, based on the timestamps associated with the one or more events of the first type and the timestamps associated with the one or more events of the second type.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: September 3, 2019
    Assignee: Facebook, Inc.
    Inventors: Jordan William Frank, Hongyu Liang, Itamar Rosenn, Aleksander Gorajek, Thomas M. Lento, Fanghua Li, Siyang Chen, Vishwas Badarinath Sharma, Paul Ashton Jones, Zoe Abrams Bayen
  • Publication number: 20190201324
    Abstract: An injectable drug delivery device includes a core containing one or more drugs and one or more polymers. The core may be surrounded by one or more polymer outer layers (referred to herein as “coatings,” “skins,” or “outer layers”). In certain embodiments, the device is formed by extruding or otherwise preforming a polymeric skin for a drug core. The drug core may be co-extruded with the skin, or inserted into the skin after the skin has been extruded, and possibly cured. In other embodiments, the drug core may be coated with one or more polymer coatings. These techniques may be usefully applied to fabricate devices having a wide array of drug formulations and skins that can be selected to control the release rate profile and various other properties of the drugs in the drug core in a form suitable for injection using standard or non-standard gauge needles.
    Type: Application
    Filed: December 27, 2018
    Publication date: July 4, 2019
    Applicant: EyePoint Pharmaceuticals, Inc.
    Inventors: Kang-Jye CHOU, Hong GUO, Paul ASHTON, Robert W SHIMIZU, David A WATSON
  • Patent number: 10300114
    Abstract: The present invention relates to sustained release drug delivery systems, medical devices incorporating said systems, and methods of use and manufacture thereof. The inventive systems feature bioerodible drug delivery devices that include biocompatible solid and biocompatible fluid compositions to achieve desired sustained release drug delivery.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: May 28, 2019
    Assignee: EyePoint Pharmaceuticals US, Inc.
    Inventors: Hong Guo, Jianbing Chen, Dongling Su, Paul Ashton
  • Publication number: 20180159944
    Abstract: Systems, methods, and non-transitory computer readable media can obtain a first event stream including one or more events of a first type, where each event of the first type is associated with a timestamp. A second event stream including one or more events of a second type can be obtained, where each event of the second type is associated with a timestamp. The first event stream and the second event stream can be merged to generate information associated with a metric relating to a system, based on the timestamps associated with the one or more events of the first type and the timestamps associated with the one or more events of the second type.
    Type: Application
    Filed: December 7, 2016
    Publication date: June 7, 2018
    Inventors: Jordan William Frank, Hongyu Liang, Itamar Rosenn, Aleksander Gorajek, Thomas M. Lento, Fanghua Li, Siyang Chen, Vishwas Badarinath Sharma, Paul Ashton Jones, Zoe Abrams Bayen
  • Patent number: 9980911
    Abstract: The invention comprises a composition comprising a bioerodible porous silicon-based carrier material wherein the carrier material carries at least one large molecule therapeutic agent and at least one amorphous sugar, optionally further comprising a crystallization inhibitor. The composition may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The composition may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: May 29, 2018
    Assignee: PSIVIDA US, INC.
    Inventors: Christian Barnett, Paul Ashton, Leigh T. Canham
  • Patent number: 9962396
    Abstract: The invention provides a biodegradable drug-eluting particle useful for the delivery of diagnostic or therapeutic agents. In certain embodiments, the drug-eluting particle of the invention comprises a biodegradable porous silicon body, a reservoir formed within the porous silicon body having at least one opening to an exterior of the body, wherein the reservoir contains a therapeutic or diagnostic agent, and an agent-permeable seal disposed over the at least one opening. The invention further provides a method for treating a patient to obtain a desired local or systemic physiological or pharmacological effect comprising administering a sustained release drug delivery particle of the invention. The invention also provides methods of fabricating a drug-eluting particle for releasing therapeutic agents.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: May 8, 2018
    Assignee: pSivida US, Inc.
    Inventors: Paul Ashton, Hong Guo, Jianbing Chen, Leigh T. Canham
  • Patent number: 9849085
    Abstract: A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of an effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir including the effective agent, an impermeable tube which encloses portions of the reservoir, and a permeable member at an end of the tube.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: December 26, 2017
    Assignee: PSIVIDA US INC.
    Inventors: Hong Guo, Paul Ashton
  • Patent number: 9808421
    Abstract: This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: November 7, 2017
    Assignee: PSIVIDA US, INC.
    Inventors: Paul Ashton, Leigh T. Canham, Christian Barnett
  • Publication number: 20170128464
    Abstract: The invention provides a biodegradable drug-eluting particle useful for the delivery of diagnostic or therapeutic agents. In certain embodiments, the drug-eluting particle of the invention comprises a biodegradable porous silicon body, a reservoir formed within the porous silicon body having at least one opening to an exterior of the body, wherein the reservoir contains a therapeutic or diagnostic agent, and an agent-permeable seal disposed over the at least one opening. The invention further provides a method for treating a patient to obtain a desired local or systemic physiological or pharmacological effect comprising administering a sustained release drug delivery particle of the invention.
    Type: Application
    Filed: November 7, 2016
    Publication date: May 11, 2017
    Applicant: pSivida US. Inc.
    Inventors: Paul Ashton, Hong Guo, Jianbing Chen, Leigh T. Canham
  • Patent number: 9603801
    Abstract: The invention comprises a composition comprising a bioerodible porous silicon-based carrier material wherein the carrier material carries at least one large molecule therapeutic agent and at least one amorphous sugar, optionally further comprising a crystallization inhibitor. The composition may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The composition may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 28, 2017
    Assignee: pSivida US, Inc.
    Inventors: Christian Barnett, Paul Ashton, Leigh T. Canham
  • Publication number: 20170049703
    Abstract: The invention comprises a composition comprising a bioerodible porous silicon-based carrier material wherein the carrier material carries at least one large molecule therapeutic agent and at least one amorphous sugar, optionally further comprising a crystallization inhibitor. The composition may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The composition may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Application
    Filed: April 29, 2016
    Publication date: February 23, 2017
    Inventors: Christian Barnett, Paul Ashton, Leigh T. Canham
  • Patent number: 9566336
    Abstract: The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: February 14, 2017
    Assignee: pSivida US, Inc.
    Inventors: Dongling Su, Paul Ashton, Jianbing Chen
  • Publication number: 20170035690
    Abstract: This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Application
    Filed: October 20, 2016
    Publication date: February 9, 2017
    Inventors: Paul Ashton, Leigh T. Canham, Christian Barnett
  • Publication number: 20160346211
    Abstract: This invention discloses bioerodible delivery compositions for delivering peptide therapeutic agents. The delivery compositions comprise a porous silicon-based carrier material loaded with the therapeutic agent. The delivery compositions may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The delivery compositions may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 1, 2016
    Inventors: Paul Ashton, Gerard Riedel, Hong Guo
  • Publication number: 20160324836
    Abstract: Disclosed are compositions and methods related to the use of kinase inhibitors in treating macular degeneration and/or retinal vein occlusion.
    Type: Application
    Filed: May 5, 2016
    Publication date: November 10, 2016
    Inventor: Paul Ashton
  • Patent number: 9486459
    Abstract: The invention provides a biodegradable drug-eluting particle useful for the delivery of diagnostic or therapeutic agents. In certain embodiments, the drug-eluting particle of the invention comprises a biodegradable porous silicon body, a reservoir formed within the porous silicon body having at least one opening to an exterior of the body, wherein the reservoir contains a therapeutic or diagnostic agent, and an agent-permeable seal disposed over the at least one opening. The invention further provides a method for treating a patient to obtain a desired local or systemic physiological or pharmacological effect comprising administering a sustained release drug delivery particle of the invention. The invention also provides methods of fabricating a drug-eluting particle for releasing therapeutic agents.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: November 8, 2016
    Assignee: pSivida US, Inc.
    Inventors: Paul Ashton, Hong Guo, Jianbing Chen, Leigh T. Canham
  • Publication number: 20160317438
    Abstract: Disclosed are compositions and methods related to the use of kinase inhibitors in treating macular degeneration and/or retinal vein occlusion.
    Type: Application
    Filed: April 29, 2016
    Publication date: November 3, 2016
    Inventor: Paul Ashton